2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2722

The down Syndrome Arthropathy Cohort in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2400

The Effect of Co-medication with Methotrexate and Other Conventional Synthetic Disease Modifying Anti-rheumatic Drugs on First Tumor Necrosis Inhibitor Drug Survival in Patients with Rheumatoid Arthritis: Results Form a Nationwide Registry

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2367

The Effect of DMARDs on Cardiovascular Outcomes in Rheumatoid Arthritis: A Systematic Literature Review

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2392

The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2265

The Effects of Message Framing on Patients’ Perceptions and Willingness to Switch to a Biosimilar

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 1943

The Emerging Regulatory Function of microRNA146a in Bone Biology and Osteoporosis

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 1936

The Expression of the Interferon Inducible Gene SERPING1 Is Reduced by Rituximab and Correlates with Clinical Response in Systemic Lupus Erythematosus

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2081

The Health-promoting Potential of Everyday Activities: Preliminary Results from an Exploratory Study of Adults with and Without Inflammatory Arthritis

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases – ARP

9:00AM-11:00AM: Abstract Number: 2091

The High Dose Influenza Vaccine Increases Immune Protection in Both Adults and Elderly Seropositive RA Patients

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2507

The Impact of Psoriasis Severity on Outcomes Among Psoriatic Arthritis Patients Receiving Adalimumab

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2308

The Interaction Between Human Leukocyte Antigen Class II Alleles and Seroprotection to Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A post-hoc Analysis

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 1948

The Mechanism of DC-STAMP-Mediated Signaling in Cell-Cell Fusion and Osteoclast Maturation

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2076

The Opioid Epidemic: The Rheumatology Response to Management of Chronic Pain

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

9:00AM-11:00AM: Abstract Number: 1949

The p.R321C Mutation in P62 Associated with Paget’s Disease of Bone Leads to a Change of Localization of the Protein in Human Osteoclasts

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2450

The Paradoxical Effect of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].